Indolent B-Cell Lymphoma
Indolent B-Cell Lymphoma
The latest news, research, and perspectives in indolent B-cell lymphoma. This diverse group of slow-growing non-Hodgkin lymphomas form in B cells and include follicular lymphoma, hairy cell leukemia, and marginal zone lymphoma.
Melissa BadamoIndolent B-Cell Lymphoma | July 8, 2024
Odronextamab showed durable response rates and an acceptable safety profile in the phase I ELM-1 and phase II ELM-2 trials.
Read More
Melissa BadamoIndolent B-Cell Lymphoma | June 28, 2024
The approval was based on results from the EPCORE® NHL-1 trial, in which epcoritamab achieved an ORR of 82%.
Melissa BadamoIndolent B-Cell Lymphoma | May 8, 2024
Intravenous mosunetuzumab was administered in 21-day cycles, with step-up dosing integrated in cycle one.
Geoff Chong, MDIndolent B-Cell Lymphoma | May 7, 2024
The ELM-2 trial studied odronextamab in patients with relapsed or refractory follicular lymphoma.
Patrick DalyFollicular Lymphoma | March 7, 2024
Common adverse reactions to zanubrutinib observed across studies included decreased neutrophil and platelet counts.
Patrick DalyIndolent B-Cell Lymphoma | March 6, 2024
Real-world treatment outcomes with bendamustine in indolent B-cell non-Hodgkin lymphoma were similar to those in trial data.
Leah SherwoodIndolent B-Cell Lymphoma | March 28, 2024
Patients with LBCL who received CAR T-cell therapy earlier in treatment had lower occurrences of severe neutropenia.
Melissa BadamoFollicular Lymphoma | February 16, 2024
At a median follow-up of 18.1 months, the ORR and CR rates were both 95.7% following liso-cel treatment.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | March 15, 2024
Drs. Saurabh Dahiya and Jay Spiegel stop by The HemOnc Pulse to discuss the recent news on CAR-T therapies and the FDA.
Blood Cancers Today Staff WritersIndolent B-Cell Lymphoma | February 2, 2024
Cancer Research & Treatment Fund (CR&T) invests in research related to the prevention and treatment of blood cancers.
Melissa BadamoIndolent B-Cell Lymphoma | February 2, 2024
The trial studied a fixed-duration regimen of mosunetuzumab plus lenalidomide in follicular lymphoma.
Melissa BadamoIndolent B-Cell Lymphoma | February 14, 2024
Among 26 response-evaluable patients, the best overall response rate was 96% and the complete response rate was 81%.
Patrick DalyIndolent B-Cell Lymphoma | December 22, 2023
Lenalidomide, rituximab, and ibrutinib was effective as a first-line therapy for patients with follicular lymphoma and MZL.
Patrick DalyIndolent B-Cell Lymphoma | December 22, 2023
Around two-thirds of patients with follicular lymphoma receive at least two lines of therapy during their lifetime.
Patrick DalyIndolent B-Cell Lymphoma | December 22, 2023
Orelabrutinib induced high response rates and sustained remission in relapsed or refractory marginal zone lymphoma,
Patrick DalyIndolent B-Cell Lymphoma | February 16, 2024
It included 21 patients with lymphoma with a median age of 57 who had received a median of four prior lines of therapy.
Melissa BadamoIndolent B-Cell Lymphoma | December 13, 2023
Researchers reviewed data on gender, race/ethnicity, zip codes to estimate poverty level, and other factors.
Blood Cancer TalksBlood Cancer Talks | December 5, 2023
Dr. Dickinson joins "Blood Cancer Talks" hosts to discuss phase I and II trials on DLBCL, follicular lymphoma, and more.
Melissa BadamoIndolent B-Cell Lymphoma | December 4, 2023
Researchers assessed the number of patients who received subsequent treatment after tirabrutinib discontinuation.
Melissa BadamoIndolent B-Cell Lymphoma | October 18, 2023
The findings "may contribute to future improved risk assessment and personalized management strategies for patients."
Editorial Board